O Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul iniciou suas atividades em outubro de 1976. O HSL é um hospital geral, de natureza filantrópica, que assiste a pacientes adultos e pediátricos, abrangendo praticamente todas as especialidades médicas.

During the past decade, União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 1 clinical trials were completed, i.e. on average, 8.3% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 1 clinical trials were completed. i.e. 9.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Actelion" with 2 trials sponsored, "Regeneron Pharmaceuticals" with 2 trials sponsored, "Janssen Vaccines & Prevention B.V." with 1 trials sponsored and "Matthew Neal MD" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS" #1 collaborator was "ISA Pharmaceuticals B.V." with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Advanced or Metastatic Non-small Cell Lung Cancer" (1 trials), "Cervical Cancer" (1 trials), "Covid19" (1 trials) and "Cutaneous Squamous Cell Carcinoma" (1 trials). Many other conditions were trialed in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS" in a lesser frequency.

Most popular intervention types in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS" are "Drug" (11 trials), "Biological" (3 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Amivantamab" (3 trials), "Placebo" (3 trials), "Cemiplimab" (2 trials), "Lazertinib" (2 trials) and "Ad26.RSV.preF" (1 trials). Other intervention names were less common.

The vast majority of trials in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS" are 11 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".